{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002780","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.523063+00:00","generated_at":"2026-06-18T13:21:15.750401+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Elevation Oncology amends bylaws for universal proxy rules and DGCL updates","bullets":["Board approved amended bylaws effective March 3, 2023, to comply with SEC universal proxy rules.","New provisions require stockholders to certify compliance with Rule 14a-19 and provide evidence 5 business days before meeting.","Advance notice bylaws updated: additional disclosures, nominee interview requirement, and limit on nominees to board seats.","Changes align with recent Delaware law amendments on electronic notice, adjournment, and stockholder lists.","Added emergency bylaw provision for director quorum during crises; other ministerial and clarifying updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002780","json":"https://secwatch.observer/filing/0001558370-23-002780.json","markdown":"https://secwatch.observer/filing/0001558370-23-002780.md","text":"https://secwatch.observer/filing/0001558370-23-002780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023002780/0001558370-23-002780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023002780/elev-20230303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:21:15.750401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12cd26e0409b7bc1693bc9986078046fd9eb19e9","claim":"Elevation Oncology, Inc.: The Company amended and restated its bylaws to address universal proxy rules, update advance notice provisions, conform to recent DGCL amendments, and make other changes (effective 2023-03-03).","evidence_excerpt":"On March 3, 2023, in connection with the effectiveness of new U.S. Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Elevation Oncology, Inc. (the “Company”), the Company’s board of directors approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023002780/0001558370-23-002780-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-03"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}